VOQP Projected Dividend Yield

VioQuest Pharmaceuticals Inc ( OTCBB : VOQP )

VioQuest Pharmaceuticals is engaged in acquiring technologies for purposes of development and commercialization of pharmaceutical drug candidates for the treatment of oncology and antiviral diseases and disorders. Co. operates under one distinct business unit: Drug Development. As of Dec 31 2006, Co. had the right to develop and commercialize two oncology drug candidates, VQD-001 and VQD-002. In collaboration with the U.S. Army, Co. is developing VQD-001, a pentavalent antimonial drug for the treatment of leishmaniasis. Co. is also developing VQD-002, a nucleoside analog, for the treatment of metastatic and refractory solid tumors including colorectal, pancreatic, breast and ovarian tumors.

20 YEAR PERFORMANCE RESULTS